In vitro susceptibility study of micelial fungal and yeast isolates to itraconazole and voriconazole;Estudio de la sensibilidad in vitro de aislamientos clínicos de mohos y levaduras a itraconazol y voriconazol

Revista Iberoamericana de Micologia

Volumn 22, Issue 2, 2005, Pages 105-109

  Morera López, Yolanda ^a   Torres Rodriguez, Josep María ^a,b   Jiménez Cabello, Teresa ^a  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Filamentous fungi; In vitro susceptibility; Itraconazole; Voriconazole; Yeast

Indexed keywords

ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG SENSITIVITY; FUNGUS; FUNGUS ISOLATION; IN VITRO STUDY; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MYCELIUM; NONHUMAN; RHIZOPUS; SCEDOSPORIUM APIOSPERMUM; SPOROTHRIX SCHENCKII; YEAST;

ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; FILOBASIDIELLA NEOFORMANS; FUNGI; RHIZOPUS STOLONIFER; SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS;

EID: 23144437072     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(05)70018-8     Document Type: Article

References (25)

1. Berenguer J, Rodríguez Tudela JL, Richard C, Alvarez M, Sanz MA, Gaztelurrutia L, Ayats J, Martínez Suarez JV. Deep infections caused by Scedosporium prolificans: a report on 16 cases in Spain and a review of the literature. Medicine 1997; 76: 256-265.
2. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33: 83-90.
3. Cuenca-Estrella M, Rodríguez D, Almirante B, Morgan J, Planes AM, Almela M, Mensa J, Sánchez F, Ayats J, Jiménez M, Salvado M, Warnock DW, Pahissa A, Rodríguez JL. In vitro susceptibilities of bloodstream isolates of Candida sp to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55: 194-199.
4. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE, Eurofung network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45-52.
5. Drago M, Scaltrito MM, Morace G, GISIA-2 Group. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis 2004; 23: 619-624.
6. Drago M, Scaltrito MM, Cariani L, Morace G. In vitro testing of Aspergillus fumigatus clinical isolates for susceptibility to voriconazole, amphotericin B and itraconazole comparison of Sensititre versus NCCLS M38-A using two different inocula. J Chemother 2004; 16: 474-478.
7. Espinel-Ingroff A. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 2001; 39: 1360-1367.
8. Garcia-Martos P, Garcia-Agudo L, Gutierrez-Calzada J. Actividad in vitro de anfotericina B, itraconazol y voriconazol frente a 20 especies de Aspergillus empleando el método de microdilución Sensititre. Enferm Infecc Microbiol Clin 2005; 23: 15-18.
9. Ghosh A, Chakrabarti A, Hemashettar BM, Maiti PK. In vitro susceptibility pattern of Sporothrix schenckii strains isolates from three centers in India. Indian J Med Res 2001; 113: 214-220.
10. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42: 741-745.
11. Mc Ginnis MR, Nordoff N, Li RK, Passarell L, Warnock DW. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med Mycol 2001; 39: 369-371.
12. Martin-Mazuelos E, Peman J, Valverde A, Chaves M, Serrano MC, Canton E. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother 2003; 52: 365-370.
13. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Verweij PE. Comparison of the Etest and the sensititre colorimetric method with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2002; 40: 2876-2885.
14. Morera Y, Torres-Rodríguez JM, Jiménez T. Antifungal susceptibilities of 113 clinical isolates of Cryptococcus neoformans and Candida sp to the new antifungal Albaconazole (UR9825) respect to voriconazole and fluconazole. Trends in Medical Mycology. Intern Proceedings. Amsterdam, Monduzzi Ed., 2003:143-147.
15. nd Ed. Wayne, PA, NCCLS, 2002.
16. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium forming filamentous fungi: Approved standard M38-A. Wayne, PA, NCCLS, 2002.
17. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones NR. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 78-83.
18. Pfaller MA, Messer SA, Mills K, Bolmstrom A. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol 2000; 38: 3359-3361.
19. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to tose of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032-1037.
20. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
21. Swinne D, Watelle M, Van der Flaes M, Nolard N. In vitro activities of voriconazole (UK-109,496), fluconazole, itraconazole and amphotericin B against 132 non albicans bloodstream yeast isolates (CANARI study). Mycoses 2004; 47: 177-183.
22. Swinne D, Watelle M, Nolard N In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non-Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22: 24-28.
23. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, Goto T, Tomishima M, Ohki H, Yamada A, Kawabata K, Takasugi H, Sakane K, Tanaka H, Matsumoto F, Kuwahara S. In vitro activities of a new lipppeptide antifungal agent, FK463 against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62.
24. Vandewoude K, Vogelaers D, Decruyenaere J, Jaqmin P, De Beule K, Van Peer A, Woesternborghs R, Groen K, Lolardyn F. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrobial Agents Chemother 1997; 41: 2714-2718.
25. Zeng J, Kamei K, Zheng Y, Nishimura K. Susceptibility of Pseudallescheria boydii and Scedosporium apiospermium to new antifungal agents. Nippon Ishinkin Gakkai Zasshi 2004; 45: 101-104.